Sun Pharma Gets CDSCO Panel Approval to Conduct Phase III Study of Oral Semaglutide
- 25 October 2025
- 1 week ago
Study confirms cardiovascular benefits of semaglutide beyond weight loss: LANCET
- 25 October 2025
- 1 week ago
FDA Approves Oral Semaglutide for Cardiovascular Risk Reduction in Type 2 Diabetes
- 23 October 2025
- 1 week ago
CDSCO Panel Seeks More Toxicity Data from Macleods on Semaglutide Injection Pre-Filled Pens
- 23 October 2025
- 1 week ago
Biocon Told to Submit Detailed Toxicity, SAE Data on Semaglutide Prefilled Pen After Animal Deaths
- 21 October 2025
- 1 week ago
Alkem Labs Gets CDSCO Panel Nod for conducting Phase III study of Semaglutide tablet
- 14 October 2025
- 2 weeks ago
CDSCO Panel seeks clarifications from Novo Nordisk on IcoSema phase IIIb clinical study protocol
- 11 October 2025
- 3 weeks ago
Recent News
Nanotechnology Reverses Alzheimer's Symptoms in Mi...
- 03 November, 2025
Gum disease could silently cause serious brain dam...
- 03 November, 2025
Can Early-Day Fasting Significantly Boost Metaboli...
- 03 November, 2025
Delhi HC bars doctor from running medical centre d...
- 03 November, 2025
Daily Newsletter
Get all the top stories from Blogs to keep track.









